Board of Directors

According to Saniona's Article of Associations, the Board of Directors shall consist of not less than three and not more than eight members. Currently, the Board of Directors consist of six members including the chairman.

 

 

J. Donald deBethizy (born 1950)

Chairman of the Board since 2018

Education: Ph.D. and M.Sc. in Toxicology from Utah State University and a B.Sc. in Biology from the University of Maryland

Other assignments: Chairman of the Board of Saniona A/S, President of White City Consulting ApS, Chairman of the Boards of Albumedix A/S and Noxxon Pharma NV (ALNOX.EN Paris), Board member of argenx N.V. (ARGX BR), Newron Pharmaceuticals SpA (NWRN.SWX) and Proterris, Inc.

Previous assignments: President and CEO of Santaris Pharma A/S. Executive Chairman of Contera Pharma ApS. Member of the Board of Asceneuron SA, Biosource Inc., Enbiotix Inc., LigoCyte Pharmaceuticals Inc., Rigontec GmbH, Serendex Pharmaceuticals A/S, Targacept Inc. and Albumedix A/S. He was also the Co-Founder and CEO of Targacept, Inc., a NASDAQ-listed U.S. biotechnology company from 1997-2012

No. of shares: 0 (0)

No. of warrants: 217,625 (0)

Non-affiliated to the management, the company and major shareholders

 

Jørgen Drejer (born 1955)

Board member and CEO since 2014 and Co-Founder of the company

Education: PhD in neurobiology

Other assignments: Member of the Board and CEO of Saniona A/S. Member of the Board of 2CureX AB.

Previous assignments: Executive Vice President, Research Director and Co-Founder of NeuroSearch A/S. Chairman of the Board of Delta Reader A/S. Member of the Board of Atonomics A/S, Delta, NsGene A/S, Origio A/S, Poseidon Pharmaceuticals A/S, Zgene A/S, Azign Bioscience A/S, Ellegaard Göttingen Minipigs ApS and Monta Biosciences A/S

No. of shares: 2,344,711 (2,344,711) privately owned

Affiliated to the management, the company and major shareholders

 

 

Anna Ljung (born 1980)

Member of the board and chairman of the Audit Committee since 2018

Education: M.Sc. in Economics and Business Administration from the Stockholm School of Economics

Other assignments: Member of the board of Saniona A/S. CFO of Moberg Pharma AB.

Previous assignments: CFO of Athera Biotechnologies AB, CFO of Lipopeptide AB and independent consultant in the field of technology licensing

No. of shares: 0 (0)

No. of warrants: 4,000 (0)

Non-affiliated to the management, the company and major shareholders

 

Claus Bræstrup (born 1945)

Member of the Board since 2014. Chairman of the board in 2014-2018 and Co-Founder of the company

Education: Doctor of Medicine and graduate in biochemistry

Other assignments: Member of the Board of Saniona A/S. Board member of and Evotec AG. and CEO of Kastan Aps

Previous assignments: CEO of H. Lundbeck A/S, Executive Vice President for Research and Development of H. Lundbeck A/S. CEO of Nordic Biotech General Partner II ApS. Chairman of the Board of Directors of Probiodrug AG. Member of the Board of Santaris Pharma A/S, Gyros AB, Bavarian Nordic A/S and Evolva Holding SA

No. of shares: 735,700 (735,700) privately owned.

Non-affiliated to the management, the company and major shareholders

 

Carl Johan Sundberg (born 1958)

Member of the Board since 2015

Education: MD

Other assignments: Member of the Board of Saniona A/S. Professor at the Department of Physiology & Pharmacology at Karolinska Institutet, Stockholm, Sweden. Board member of Cobra Biologics Holding AB, Arne Ljungqvist Anti-doping Foundation AB and Medkay Konsulting AB, partner in Medkay Konsulting HB. Head of the Department of Learning, Informatics, Management and Ethics at Karolinska Institutet, member of the International Olympic Committee´s Medical Commission and an elected member of the Royal Swedish Academy of Engineering Sciences (IVA)

Previous assignments: Board member of Alfta Rehab Holding AB, KI Management AB, KI Management Partners AB, Karolinska Development AB and NsGene A/S

No. of shares: 0 (0)

No. of warrants: 4,000 (0)

Non-affiliated to the management, the company and major shareholders

 

 

 

Edward C. Saltzman (born 1955)

Member of the Board since 2019

Education: Degree from New York University

Other assignments: Executive Chairman of Cello Health BioConsulting, previously Defined Health, after having led the sale of Defined Health to Cello Health in 2017. Serves as a Venture Advisor to the Israel Biotech Fund and is a board member of Vidac Pharmaceuticals Ltd.

No. of shares: 0 (0)

No. of warrants: 0 (0)

Non-affiliated to the management, the company and major shareholders